As part of the settlement, Merck has agreed to:
-- Pay $58 million to the states involved.
-- No longer engage in "ghostwriting."
-- Refrain from using scientific data deceptively when marketing to
doctors.
-- Delay any direct-to-consumer television advertising for a pain
medication if recommended by the FDA.
-- Submit all television advertising campaigns to the FDA before release
for review and to adhere to any recommendations by the FDA.
In addition to Pennsylvania, this settlement includes Arkansas, Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Nebraska, Nevada, New Jersey, North Carolina, North Dakota, Ohio, Oregon, South Carolina, South Dakota, Tennessee, Texas, Vermont, Washington, Wisconsin and the District of Columbia.
The agreement was filed in Commonwealth Court by Chief Deputy Attorney General Thomas M. Devlin and Deputy Attorney General Nicole L. VanOrder of the Attorney General's Health Care Section.
EDITOR'S NOTE: For a copy of the agreement, contact the Attorney General's office at 717-787-5211.
CONTACT: Eric Shirk
Assistant Press Secretary
717-787-5211 (Cell) 717-480-0224
| SOURCE Pennsylvania Office of Attorney General Copyright©2008 PR Newswire. All rights reserved |